TRAITEMENT DU SYNDROME DE FATIGUE AVEC DES INHIBITEURS DE LA CHOLINESTERASE

TREATMENT OF FATIGUE SYNDROME WITH CHOLINESTERASE INHIBITORS

Abrégé anglais

2108880 9220327 PCTABS00017
The use of a pharmaceutically acceptable cholinesterase inhibitor
or a prodrug therefor for the treatment of fatigue syndromes,
including Chronic Fatigue Syndrome, Post-infectious Fatigue
Syndromes, fatigue syndromes associated with human immunodeficiency
virus (HIV) infection or with preeclampsia. The acetyl cholinesterase
is preferably one that acts substantially selectively at
nicotinic receptor sites, and which has selectivity for acetyl
cholinesterase opposed to butyryl cholinesterase, e.g. galanthamine or a
galanthamine derivative.

Revendications

WO 92/20327 PCT/DK92/00160
47
AMENDED CLAIMS
[received by the International Bureau on 15 October 1992 (15.10.92);
original claims 1-7 unchanged; original claims 7(second occurrence)-34
replaced by amended claims 8-36 (8 pages)]
1. The use of a pharmaceutically acceptable cholinesterase
inhibitor or a prodrug therefor for the preparation of a
pharmaceutically acceptable composition for the treatment
of fatigue syndrome.
2. The use according to claim 1 wherein the fatigue syn-
drome is a severe fatigue syndrome.
3. The use according to claim 1, wherein the fatigue syn-
drome is the Chronic Fatigue Syndrome.
4. The use according to claim 3, wherein the Chronic Fati-
gue Syndrome, in addition to the fatigue symptom, comprises
one or more symptoms selected from sleep disturbances,
myalgia, mood disturbances, lack of concentration and
dizziness.
5. The use according to claim 1, wherein the fatigue syn-
drome is a Post-infectious Fatigue Syndrome.
6. The use according to claim 1, wherein the fatigue syn-
drome is the fatigue syndrome associated with human immuno-
deficiency virus (HIV) infection.
7. The use according to claim 1, wherein the fatigue syn-
drome is the fatigue syndrome associated with preeclampsia.
8. The use according to any of claims 1-6, wherein the
cholinesterase inhibitor is selected from the group con-
sisting of galanthamine and galanthamine derivatives, nor-
galanthamine and norgalanthamine derivatives, epigalan-
thamine and epigalanthamine derivatives, physostigmine,
tacrine and tacrine analogues, fasciculin, metrifonate,
heptyl-physostigmine, norpyridostigmine, norneostigmine,
and huperzine, or a prodrug therefor.

WO 92/20327 PCT/DK92/00160
48
9. The use according to claim 1, in which the cholin-
esterase inhibitor is an acetylcholinesterase inhibitor
which is active substantially selectively at nicotinic
receptor sites.
10. The use according to claim 1, in which the acetylcho-
linesterase inhibitor is one which has an at least 10-fold
selectivity for acetylcholinesterase as opposed to butyryl-
cholinesterase.
11. The use according to claim 10, in which the acetylcho-
linesterase inhibitor is one which has an at least 20-fold
selectivity for acetylcholinesterase as opposed to butyryl-
cholinesterase.
12. The use according to claim 10, in which the acetyl-
cholinesterase inhibitor is one which has an at least 40-
fold selectivity for acetylcholinesterase as opposed to
butyrylcholinesterase.
13. The use according to claim 9, in which the acetyl-
cholinesterase inhibitor is one which, upon administration
in an amount of 10 mg to a healthy adult, results in in-
hibition of at least 40% of the acetylcholinesterase ac-
tivity in erythrocytes from the adult and no substantial
inhibition of butyrylcholinesterase therein.
14. The use according to claim 13, in which the acetyl-
cholinesterase inhibitor is one which, when administered in
an amount of 10 mg to an adult, results in inhibition of at
least 50% of the acetylcholinesterase activity in erythro-
cytes from the adult.
15. The use according to any of the preceding claims, in
which the cholinesterase inhibitor is one which is capable
of passing the blood-brain barrier in humans.

WO 92/20327 PCT/DK92/00160
49
16. The use according to any of the preceding claims, in
which the cholinesterase inhibitor is one which, upon admi-
nistration to a human, increases the cortisol level in the
human.
17. The use according to claim 1, in which the cholin-
esterase inhibitor is galanthamine or a functional equiva-
lent thereof.
18. The use according to claim 17, in which the functional
equivalent is a compound which is an acetylcholinesterase
capable of passing the blood brain barrier, which has an at
least 10-fold selectivity for acetylcholinesterase as
opposed to butyrylcholinesterase.
19. The use of a galanthamine or a galanthamine salt or a
galanthamine derivative for the preparation of a pharma-
ceutically acceptable composition for the treatment of
fatigue syndrome.
20. The use according to claim 19, in which the compound
is a galanthamine derivative of the general formula I
<IMG> I
wherein the broken line represents an optionally present
double bond in one or the two of the positions shown, R1
and R2 are each selected independently from the group con-
sisting of hydrogen, hydroxyl, amino or alkylamino, cyano,
sulfhydryl, alkoxy of 1-6 carbon atoms, alkylthio, aryloxy,

WO 92/20327 PCT/DK92/00160
arylthio, R5-substituted aryloxy, R5-substituted arylthio,
aralkoxy, an aliphatic or aryl carbamyl group wherein the
aliphatic or aryl moiety may be R5 substituted or unsub-
stituted, aralkylthio, R5-substituted aralkoxy, R5-substi-
tuted aralkylthio, aryloxymethyl, R5-substituted aryloxy-
methyl, alkanoyloxy, hydroxy-substituted alkanoyloxy,
benzoyloxy, R5-substituted benzoyloxy, aryloxycarbonyl and
R5-substituted aryloxycarbonyl, R1 may also be alkyl of up
to 14 carbon atoms, or hydroxymethyl, R2 may also be car-
boxymethyl, provided that at least one of R1 and R2 is
hydroxy, amino or alkylamino unless R7 or R8 is hydroxy-
methyl,
R3 is hydrogen, straight or branched chain alkyl of 1-6
carbon atoms, cycloalkylmethyl, phenyl, R5-substituted
phenyl, alkylphenyl, R5-substituted alkylphenyl, hetero-
cyclyl selected from .alpha.- or .beta.-furyl, .alpha.- or .beta.-thienyl or
thenyl, pyridyl, pyrazinyl, and pyrimidyl, alkyl-hetero-
cyclyl or R'-substituted heterocyclyl, where R' is alkyl or
alkoxy,
each R4 is independently selected from hydrogen, hydroxyl,
sulfhydryl, alkyl, aryl, aralkyl, alkoxy, mercaptoalkyl,
aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro,
amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro,
chloro, bromo, iodo, and trifluoromethyl,
R5 is selected from the same groups as R4,
R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4
carbon atoms with the proviso that when R6 is in position 7
or 9, it is not halo,
R7 is selected from the same groups as R4 or may be hy-
droxyalkyl of 1-2 carbon atoms,
R8 is hydrogen or hydroxymethyl,

WO 92/20327 PCT/DK92/00160
51
R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2
is hydroxyl, R9 may be a moiety of formula I wherein R9 is
hydrogen and R2 is a linking bond; or
R2 and R9 may jointly form semicarbazone,
X is oxygen or NR5,
Y is nitrogen or phosphorus,
and methylenedioxy derivatives thereof with the proviso
that when X is 0, R3 is not methyl when R1 is methoxy, R2
is hydroxy, and all R4 are hydrogen,
or a pharmaceutically acceptable acid addition salts
thereof.
21. The use according to claim 19, in which the compound
is galanthamine or a derivative of galanthamine and has the
formula II
<IMG> II
wherein
R1 and R2 which may be the same or different each repre-
sents a hydrogen atom or an acyl group, such as a lower
alkanoyl group, e.g. an acetyl group or a straight-chained
or branched alkyl group, e.g. methyl, ethyl, propyl, or
isopropyl;

WO 92/20327 PCT/DK92/00160
52
R3 is a straight or branched chain alkyl, alkenyl or alk-
aryl group which is optionally substituted by a halogen
atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, amino-
alkyl, acylamino, heteroaryl, heteroaryl-alkyl, aroyl,
aryolalkyl or cyano group; and
R4 represents a hydrogen or halogen atom attached to at
least one of the ring carbons of the tetracyclic skeleton,
with the proviso that when R4 is in a position neigh-
bouring the nitrogen atom, then R4 is different from halo-
gen, and salts thereof, such as a hydrobromide, hydrochlo-
ride, methylsulphate or methiodide.
22. The use according to any of claims 19-21, wherein the
galanthamine salt is galanthamine hydrobromide.
23. The use according to any of the claims 19-22, wherein
the fatigue syndrome is a severe fatigue syndrome.
24. The use according to claim 23, wherein the fatigue syn-
drome is the Chronic Fatigue Syndrome.
25. The use according to claim 24, wherein the Chronic
Fatigue Syndrome, in addition to the fatigue symptom,
comprises one or more symptoms selected from sleep distur-
bances, myalgia, mood disturbances, lack of concentration
and dizziness.
26. The use according to claim 23, wherein the fatigue syn-
drome is a Post-infectious Fatigue Syndrome.
27. The use according to claim 23, wherein the fatigue syn-
drome is the fatigue syndrome associated with human immuno-
deficiency virus (HIV) infection.
28. The use according to claim 23, wherein the fatigue syn-
drome is the fatigue syndrome associated with preeclampsia.

WO 92/20327 PCT/DK92/00160
53
29. The use according to any of the claims 19-28, wherein
the galanthamine derivative is one which is able to cross
the blood brain barrier in humans.
30. The use according to any of claims 1-29, wherein the
cholinesterase inhibitor or the galanthamine or the galan-
thamine salt or the galanthamine derivative is administered
in the form of a pharmaceutical composition which is a
tablet, a capsule, a sustained release capsule comprising
micro capsules of the active ingredient, a solution or
suspension, a plaster for transdermal application, or a
suppository.
31. The use according to any of claims 1-29, in which the
cholinesterase inhibitor or the galanthamine or the galan-
thamine salt or the galanthamine derivative is administered
parenterally at a dosage which is equipotent with 0.1-1,000
mg of galanthamine hydrobromide per day, such as 5-1,000 mg
of galanthamine hydrobromide.
32. The use according to claim 31, in which the cholin-
esterase inhibitor is administered in a dosage which is
equipotent with to 10-500 mg of galanthamine hydrobromide
per day, such as 50-300 mg per day.
33. The use according to claim 32, in which the cholin-
esterase inhibitor is administered in a dosage which is
equipotent with 10-50, in particular 10-30, mg of galan-
thamine hydrobromide per day.
34. The use according to any of claims 1-29, in which the
cholinesterase inhibitor is administered orally in a dosage
which is equipotent with 5-2000 mg of galanthamine hydro-
bromide per day.
35. The use according to claim 34, in which the cholin-
esterase inhibitor is administered at a dosage which is

WO 92/20327 PCT/DK92/00160
54
equipotent with 10-500 mg of galanthamine hydrobromide per
day.
36. The use according to claim 35, in which the cholin-
esterase inhibitor is administered at a dosage which is
equipotent with 10-50 mg, such as 10-30 mg, of galanthamine
hydrobromide per day.

Description

- W092/20327 ~ !~ 3 ~ PCT/DK92/00160
., ~ 1
TREAT~T OF FATIGUE SYNDROME wITH CHOL~ES~U~E ~ IBITORS
SUMMARY OF THE INVENTION
The present invention relates to the use of pharmaceutical-
ly acceptable acetylcholinesterase inhibitors for the
preparation of a pharmaceutical composition for treatment
of fatigue syndromes, particularly chronic fatigue syn-
drome, such as Chronic Fatigue Syndrome (CFS), P~st-infec-
tious Fatigue Syndrome, fatigue associated with human
immunodeficiency virus infection and related syndromes such
as fatigue associated with pre-eclampsia. Preferably, the
cholinesterase inhibitors are selected from a group of
nicotinic acetylcholinesterase inhibitors such as galan-
thamine-hydrobromide, which are able to cross the blood
brain barrier in humans.
DETAILED DESCRIPTION OF INVENTION
Fatiaue syndrome
Fatigue syndrome designates a condition where fatigue (or
synonyms thereof including tiredness and weariness) is
considered to be the principal symptom of uncertain cause,
i.e. that no recognised underlying disease causes the
fatigue. Fatigue is commonly reported as having two as-
pects, namely mental fatigue and physical fatigue, where
mental fatigue is a subjective sensation characterized by
lack of motivation and of alertness and physical fatigue is
the feeling as lack of energy of strength and is often felt
in the muscles.
To be regarded as a symptom, fatigue must be complained of,
and should affect the person's functioning and be dispro-
portionate to exertion. Furthermore, it should represent a
clear change from a previous state and be persistent, or,
if intermittent, should be present more than 50% of the
time.

~ Wo92/203z7 PCT/DK92/00160
~1~88~ 2
Fatigue should be distinguished from low mood and from lack
of interest. The symptom of fatigue should not be confused
with impairment of performance as measured by physiological
or psychological testing. The physiological definition of
fatigue is a failure to sustain muscle force or power
output.
Fatigue syndromes have only recently been considered as
"real" independent diseases and not only as being caused by
an underlying disease or being complaints from neurotics or
hypochondriacs. There is an increasing interest for finding
the cause of the fatigue in order to find a medical treat-
ment. However, an effective medical treatment for fatigue
syndromes has not been available until now.
The study of fatigue performed by the present inventor
indicates that the mechanism of fatigue could be an im-
balance in the cholinergic nicotinic transmitter system,
both peripherally and centrally, actually a decrease of
acetylcholine in the central and peripheral synapses. This
is supported by the facts that several of the symptoms
often related to a fatigue syndrome are also thought to be
; caused by decrease of acetylcholine, the other symptoms
being, e.g. disturbances of sleep.
The fatigue and the other symptoms of the syndromes are
cor.templated to result from an augmentation of the acetyl-
cholinesterase in the synapsis which decreases the amountof synaptic acetylcholine, which decrease is a physiolo-
gical response to infections and inflammations (sterile
infections) because inflammations and infections cause a
decrease in the Ca2~ concentration and as explained below,
the result in a decrease in the amounts of acetylcholine
released from the presynaptic membranes.
EP 098 975 discloses a biostimulant tonic which comprises,
as the active biostimulants, creatine and hydrolyzate of
.
.
.' :' .

W092/20327 ~ 3 ~ ~
protein. The biostimulant contains 40 to 45 % by weight of
creatine, 42 to 46 % by weight of calcium-magnesium salt of
inositephosphoric acid, 10 to 12 % by weight of lyophilized
hydrolysate of Royal Jelly, and 1 to 3 % of galanthamine.
The present invention does not encompass such tonic.
EP 098 975 does not describe any phenomenon which corre-
sponds to fatigue syndrome.
Cholinergic system
Many cell membranes can be excited by specific chemical or
physiological stimuli. The common features of these proces-
ses and others carried out by excitable assemblies are:
1) The stimulus is detected by a highly specific protein
receptor, which is an integral comDonent of the excitable
membrane.
2) The specific stimulus elicits a conformational chanqe
in the receptor. As a result, the permeability of the
membrane or the activity of a membrane-bound enzyme chan-
ges. Many of the responses are highly amplified.
3) The conformational changes in the receptor and the
Z0 resulting alterations in function are reversible. There are
mechanisms that take the receptor back to its resting state
and restore its excitability.
Nerve cells interact with other nerve cells at junctions
called synapses. Nerve impulses are communicated across
most synapses by chemical transmitters, which are small,
diffusable molecules such as acetylcholine and norepine-
phrine. Acetylcholine is also the transmitter at motor end
plates (neuromuscular junctions), which are the junctions
between nerve and striated muscle.
The presynaptic membrane of a cholinergic synapse, that is
one that uses acetylcholine as the neurotransmitter ! is
, , ,, . : , , '
'
"~:

W092~20327 PCT/DK92/00160
8~ 4
. ~
separated from the postsynaptic membrane by a gap of about
500 A, called the synaptic cleft. The end of the presynap-
tic axon is filled with synaptic vesicles containing ace-
tylcholine. The arrival of a nerve impulse leads to the
release of acetylcholine into the cleft. The acetylcholinemolecules then diffuse to the postsynaptic membrane, where
they com~ine with specific receptor molecules. This produ-
ces a depolarization of the postsynaptic membrane, which is
propagated along the electrically excitable membrane of the
second nerve cell. Acetylcholine is hydrolyzed by acetyl-
cholinesterase and the polarization of the postsynaptic
membrane is restored.
Acetylcholine is synthesized near the presynaptic end of
axons by the transfer of an acetyl group from acetyl CoA
(Co-enzyme A) to choline. Some of the acetylcholine is
taken up by synaptic vesicles, whereas the remainder stays
in the cytosol. A cholinergic synaptic vesicle, which is
typically 400 A in diameter, contains about 104 acetyl-
choline molecules.
.
Acetylcholine is released from the presynaptic membrane in
form of packets containing of the order of 104 molecules.
The number of packets release depends on the potential of
the presynaptic membrane. In other words the release of
acetylcholine is an electrically controlled form of secre-
tion.
Release of acetylcholine depends on the presence of Ca2+ in
the extracellular fluid. The depolarization of the presy-
naptic membrane leads to the entry of Ca2t, which promotes
a transient fusion of the synaptic vesicle membrane and the
presynaptic membrane.
If the concentration of Ca2+ is decreased, the presynaptic
action potential releases fewer packets of acetylcholine;
the number released depends on the Ca2+ concentration. The
size of the packets released are the same, it is the amount
,
.
'
'

~ W092/20327 21~ 8 ~ $ ~ PCT/DK92/00160
of packets that are depending on the Ca2+ concentration.
Thus, the amplitude of the potential of the postsynaptic
membrane is depending on the Ca2+ concentration in the
surroundings of the presynaptic membrane.
The depolarizing signal may be switched off to restore the
excitability of the postsynaptic membrane. Acetylcholine is
hydrolyzed to acetate and choline by acetylcholinesterase.
Acetylcholinesterase is located in the synaptic cleft,
where it is bound to a network of collagen and glycosamin-
glycans derived from the postsynaptic cell. The 260-kdal
enzyme, which has an ~2~2 structure, can be readily separa-
ted from the acetylcholine receptor.
Acetylcholinesterase has a very high turnover number of
25,000s-l, which means that it cleaves an acetylcholine
molecule in 40 ~sec. The high turnover number of the enzyme
is essential for the rapid restoration of the polarized
state of the postsynaptic membrane. Synapses can transmit
l,000 impulses per second only if the postsynaptic membrane
recovers its polarization within a fraction of a millise-
cond.
Acetylcholine reacts with a specific serine residue at theactive side of acetylcholinesterase to form a covalent
acetyl-enzyme intermediate, and choline is released. The
acetyl-enzyme intermediate then reacts with water to form
acetate and regenerate the free enzyme.
Postsynaptic acetylcholine receptors may be assigned to two
classes which are clearly pharmacologically distin-
guishable. Receptors that can be stimulated by nicotine are
of the nicotinic type and may be blocked by curare, and
receptors that can be stimulated by muscarine are of the
muscarinic type and are insensitive to curare. In the
autonomic nervous system, the nicotinic receptors are found
in the ganglia whereas the muscarinic receptors are found
in the effector organs.

W092/20327 PCT/DK92~00160
6 -
2~88~0
Acetylcholinesterase is found at postsynaptic membranes,
but also in the erythrocytes and in the plasma (so-called
un-specific acetylcholinesterase or pseudo-cholinesterase
or butyrylcholinesterase).
Acetylcholinesterase inhibitors enhance the effect of
acetylcholine by inhibiting its hydrolyzation or at least
prolonging the actual time that each acetylcholine molecule
is present in the synapse. Cholinesterase inhibitors are of
course understood as synonymous to anticholinesterase, and
may be understood as a cholinesterase agonist.
Cholinergic synapses are found in the motor end plates
(neuromuscular junctions), in the sympathetic part of the
autonomic nervous system in all ganglionic synapses, at the
synapses in the adrenal medulla, and at the postsynaptic
synapses in the sweat glands. In the parasympathetic auto-
nomic nervous system acetylcholine is the transmitter in
all the ganglia as well as at postganglionic effector
synapses. Furthermore, acetylcholine is present in the
central nervous system where it is contemplated to function
as a transmitter.
The therapeutic need for compounds capable of treating the
fatigue syndrome has been increased with the understanding
of the fatigue syndromes.
It has now been found that on administration of galantha-
mine, a cholinesterase inhibitor, the fatigue disappears,
the time for disappearance of the fatigue qenerally being
proportionate to the time the fatigue has lasted.
The present invention is based on the above-mentioned
discovery and relates to the use of a cholinesterase in-
hibitor for the preparation of a pharmaceutical compositionfor the treatment of fatigue syndromes, such as severe
fatigue syndromes, in particular Chronic Fatigue Syndrome,
,
: : .

W092t20327 2 ~ PCT/DKg2/00160
Post-infectious Fatigue Syndrome, fatigue associated with
human immunodeficiency virus (HIV) infection, or fatigue
related to preeclampsia. The cholinesterase inhibitor is
preferably one which crosses the blood-brain barrier and
furthermore is selective with respect to cholinergic nico-
tinic receptor sites, such as galanthamine hydrobromide.
A cholinesterase inhibitor is understood as being a synonym
to an anticholinesterase, and furthermore, to be understood
as an cholinergic agonist or a cholinergicum.
In the present context, the term "a syndrome" designates a
complex of symptoms which appear so regularly together
that it is contemplated that they are different signs of
the same disease. The symptoms need not all appear always
in all persons suffering from the syndrome, such as will
appear from the following.
A fatigue syndrome is a syndrome where fatigue is always
present as a principal symptom often accompanied by other
symptoms as described below.
one example of a fatigue syndrome is the Chronic Fatigue
Syndrome. The term "Chronic Fatigue Syndrome" has recently
been agreed upon (Journal of the Royal Society of Medicine,
Volume 84, February 1991) as a standard term with a di-
stinct meaning, but the disease has been known for many
years under other names such as, epidemic neuromyasthesia,
idiopathic chronic fatigue and myalgia syndrome, chronic
infectious mononucleosis, benign myalgic encephalomyelitis,
post-viral fatigue syndrome, fibrositis-fibromyalgia syn-
drome, Icelandic disease, Akureyri disease, or Royal Free
Hospital disease.
According to the above-mentioned agreement, The Chronic
Fatigue Syndrome is defined by the following symptom:
' ~
~ .

W O 92/2~327 P~r/DK92/00160
2~ ~88~ 8 ~ --
- A fatigue which is the principal symptom, which has a
definite onset, and is severe, disabling and affects
both physical and mental functioning, and furthermore
the fatigue should have been present for a minimum of
6 months at which it was present for more than 50 % of
the time
and by one or more of the following symptoms which may or
may not be present:
- Sleep disturbances, which are changes in the duration
of sleep and/or quality of sleep. The changes could be
hypersomnia or increased sleep, or insomnia or reduced
sleep, (which should further be described as either
difficulty of getting off to sieep, early wakening, or
subjectively disturbed or unrefreshening sléep). The
changes of the quality of sleep is contemplated to be
due to a decrease in REM sleep, e.g. the deep sleep
which is necessary for a feeling of having a good and
refreshening sleep.
- Disability, which refers to any restriction or lack
(resulting from loss of psychological or physiological
function) of ability to perform an activity in the
manner or within the range considered normal for human
being, i.e. thinqs that people cannot do in the areas
of occupational, social and leisure activities because
of their illness. The disability should be distin-
guished from impairment of function (e.g. weak legs)
and from handicap (e.g. unable to work). Furthermore,
there should be a definite and persistent change from
a previous level of functioning.
- Mood disturbances such as depressed mood, anhedonia,
anxious mood, emotional lability and irritability, the
severity of the mood disturbances should be assessed
on standard scales. Furthermore it should be deter-
.
.
.

W092/20327 PCT/DK92/00160
^:~ 9 2~
mined whether the disorder is sufficient to meet the
diagnostic criteria for major depressive disorders.
- Myalgia, which is pain or aching felt in the muscles.
The myalgia should be disproportionate to exertion. It
should be distinguished from feelings of weakness and
pain felt in other areas such as the joints.
In the present context, the term "fatigue syndrome" desig-
nates a syndrome which, qualitatively, that is, with re-
spect to the character of the syndrome, is substantially
identical to the condition characterized in the Chronic
Fatigue Syndrome, but which auantitatively, that is, with
respect to the duration of the syndrome, has not yet, at
the time of treatment, lasted for the 6 months which con-
stitute a compulsory element of the definition of the
Chronic Fatigue Syndrome.
Thus, if a patient shows symptoms which, had they prevailed
for at least 6 months, would categorize the patient as
suffering from the Chronic Fatigue Syndrome, but which have
not yet, at the time in question, prevailed for 6 months,
the shorter duration, although bringing the syndrome out-
side the established definition of Chronic Fatigue Syndro-
me, does not bring the condition outside the definition of
fatigue syndrome as used herein.
With reference to the definition of the Chronic Fatigue
Syndrome, the fatigue syndrome definition used herein will,
thus, at least comprise the same disabling fatigue condi-
tion which (if it has lasted for at least 6 months) already
in itself would establish a condition under the definition
of the Chronic Fatigue Syndrome.
Normally, however, a fatigue condition will not be con-
sidered a syndrome unless it has had a duration and/or a
course which distinguishes it from, e.g., the fatigue
resulting from normal exertion. Thus, fatiaue syndrome in
: . . ' , ~ , ~'
-: :
.

~ W092/20327 2 ~ ~ ~ 8 ~ l~ PCT/DK92/00160
the sense of the present specification is one which is
complained of, significantly affects the person's funGtio-
ning, and represents a clear change from a previous state.
Its duration will have been at least 14 days, normally at
least one month. In the present specification and claims, a
severe fatigue syndrome is defined as a fatigue syndrome
the duration of which is at least 2 months, normally at
least 3 months.
Another example of a fatigue syndrome is the Post-infec-
tious Fatigue Syndrome which may be considered as a sub-
class of the Chronic Fatigue Syndrome. The Post-infectious
Fatigue Syndrome is defined by the same symptoms as the
Chronic Fatigue Syndrome and furthermore, a definite evi-
dence of infection at onset must have been provided and the
infection should have been corroborated by laboratory
evidence.
Yet another example of a fatigue syndrome is the fatigue
associated with human immunodeficiency virus (HIV) infec-
tion (AIDS).
A still further fatigue syndrome is the syndrome associated
with preeclampsia.
As appears from the above, the crucial feature of the
present invention is the administration of a cholinestera-
se. Compounds which function as cholinesterase inhibitors
may be divided into several groups, namely poison gases for
use in warfare, insecticides, such as malathion, and drugs.
In the present context, the term "pharmaceutically accep-
table" indicates that the cholinesterase inhibitors in
guestion are not such which will be poisonous, in other
words, they pertain to the drug group and not to the poison
group.
Pharmaceutically acceptable cholinesterase inhibitors are,
e.g., galanthamine and galanthamine derivatives, norgalan-
... . .. . ~
- ~ .

W092/20327 2 ~ $ ~ ~
thamine and norgalanthamine derivatives, epigalanthamine
and galanthamine, physostigmine, tacrine and tacrine analo-
gues, fasciculin, metrifonate, heptyl-physostigmine, nor-
pyridostigmine, norneostigmine, and huperzine or a prodrug
therefor. Some of the cholinesterase inhibitors show cer-
tain undesirable properties, such as short half life, etc.
In some cases, such deficiencies can be compensated for by
modifying the compound into a prodrug for the active com-
pound, in accordance with well-known principles for p~odrug
construction, such as introduction of hydrophilic groups to
enhance the solubility of a compound in water, thus making
it possible to formulate the compound as a an injection
solution, an introduction of lipophilic groups such as
ester groups to enhance the capability of the compound to
pass the blood-brain barrier.
The presently preferred cholinesterase inhibitor used
according to the invention is galanthamine. Galanthamine is
known as an acetylcholinesterase acting substantially only
at nicotinic receptor sites, that is, having a high selec-
tivity for acetylcholinesterase as opposed to butyrylcho-
linesterase. A more detailed discussion of galanthamine and
galanthamine derivatives is given below:
Galanthamine is a well-known acetylcholinesterase inhibitor
which is active substantially selectively at nicotinic
receptor sites and has substantially no effect on muscari-
nic receptor sides, is capable of passing the blood-brain
barrier in humans, and presents no severe side effects in
therapeutically necessary dosages.
Galanthamine and acid addition salts thereof have, for many
years, been known to have anticholinesterase properties.
Galanthamine, a tertiary alkaloid, has been isolated form
the bulbs of the Caucasian snowdrops Galantanus woronowi
(Proskurnina, N.F. and Yakoleva, A.P. 1952, Alkaloids of
Galanthus woronowi. II. Isolation of a new alkaloid. (In
Russian.) Zh. Obschchei Khim. (J.Gen.Chem.) 22, 1899-1902.
-

W092~20327 PCT/DK92/00160
2i~83~ 12 ~
Chem.abs. 47,6959, 1953. It has also been isolated from thecommon snowdrop Galanthus Nivalis (Boit, 1954).
Galanthamine has been used extensively as a curare reversal
agent in anaesthetic practice in Eastern bloc countries
(cf. review by Paskow, 1986) and also experimentally in the
West (cf. Bretagne and Valetta, 1965: Wislicki, 1967;
Conzanitis, 1971).
Pharmacokinetic studies have recently been made by Thomsen,
T. and H. Kewitz. (Selective Inhibition of Human Acetyl-
cholinesterase by Galanthamine in vitro and in vivo. LifeSciences, Vol 46, pp. 1553-1558 (1990), and, by the same
authors, Galanthamine Hydrobromide in a Long-Term Treatment
of Alzheimer's Disease. Dementia 1990, 1:46-51).
It is believed that the excellent and surprising effect
possessed by galanthamine is due to its specific profile of
properties, the most important of the known ones of which
can be summarized as follows:
- capability to pass the blood brain barrier in humans,
20 - a high selectivity for acetylcholinesterase as opposed
to butyrylcholinesterase (about 50-fold when measured
by the in vitro method by Thomsen et al., see below),
- a sufficient elimination half life to warrant duration
of an effective concentration of at least 4 hours,
probably at least 6 hours,
- a relatively low toxicity in therapeutical concentra-
tions,
- capability of being effective in doses which are
sufficiently low to keep peripheral side effects low.
., . " :

W092/20327 PCT/DK92/00160
13 ~ 3
Galanthamine must be considered as being a very desirable
drug for the treatment according to the invention: The
elimination half life of galanthamine hydrobromide is over
four hours; it shows a practically complete renal elimina-
tion. A complete elimination of metabolites and galantha-
mine takes place in 72 hours. Galanthamine has been used in
Eastern Block countries since around 1958 as an anticurare
agent in anesthesiology, and a considerably number of
patients have been treated with galanthamine without any
reported case of liver toxicity or serious side effects.
Galanthamine hydrobromide, being a tertiary amine and lipid
soluble, is absorbed rapidly from the gut and transverses
the blood brain barrier easily. The common side effects,
other than the ones related to cholinergic crisis, are
either nausea or vomiting, and a slight headache. However,
these side effects are rare, especially when care is taken
to start medication in low doses such as mentioned above.
The galanthamine can suitably be administered orally in the
form of an acid addition salt, e.g. the hydrobromide, but
other administration forms are possible and realistic, such
as is described below.
Because galanthamine has substantially no effect on the
activity at muscarinic receptor sites, as apparent from its
high selectivity for acetylcholinesterase as opposed to
butyrylcholinesterase, it will not give rise to the often
severe side effects on the heart which are associated with
cholinesterase inhibitors which have a low selectivity for
acetylcholinesterase as opposed to butyrylcholinesterase.
Galanthamine has an in vitro selectivity for acetylcholin-
esterase opposed the effect on butyrylcholinesterase of 50to 1, as reported by Thomsen, Life Sciences, Vol 46, pp.
1553-1558 (1990).
As indicated above, the amount of galanthamine is preferab-
ly adjusted individually based upon observation of the
effect of initially very low dosages. There is as consider-

~ W092/20327 PCT/DK92/00160
2 ~
14 t
able difference with respect to how sensitive individualsare to acetylcholinesterase inhibitors. Thus, the amount of
galanthamine is suitably adjusted by means of a regimen
starting at low dosages, e.g. l mg, preferably at S mg, per
S day, but, if appropriate, even as low as 0.1 mg per day, if
the dosage is well tolerated by the patient within the
first two hours the dosages is increased to, e.g. lo mg per
dosage dosed 3 to 4 times per day or in some severe cases
to 60 mg or more per day dosed over 3 or 4 times.
Because cholinergic crisis, a life-threatening dose-depen-
dant side effect of all kinds of acetylcholinesterase
inhibitors, should, by all means, be avoided, it is recom-
mended to start with the low dosages as mentioned above and
furthermore not to exceed 150 mg per day and preferably not
to exceed dosages above 60 mg per day, unless the patient
shows a very low sensitivity to acetylcholinesterase in-
hibitor, in which case higher doses, such as 200 mg per
day, could be used.
The treatment according to the invention should preferably
be continued at least for two months, such as, e.g., three
months, or until the syndrome has disappeared.
While galanthamine has, indeed, given remarkable results,
such as appears from the clinical cases given in the ex-
amples, it is justified to presume that other acetylcholin-
esterase inhibitors which are functional equivalents togalanthamine with respect to its combination of high selec-
tivity with respect to nicotinic receptor sites and capa-
bility of passing the blood brain barrier in humans in
vivo, will also show a useful combination of effect against
fatigue syndrome and acceptability in the clinic, although
it cannot be ruled out that galanthamine, galanthamine
salts and galanthamine derivatives, due to the special
conformation of the galanthamine ring system, have specific
properties which are decisive for the remarkable effect.

W092/20327 PCT/DK92/00160
In accordance with the above, compounds which are function-
al equivalents of galanthamine are defined herein as com-
; pounds which
, . .
a) possess an at least lO-fold selectivity, preferably an
at least 20-fold selectivity, more preferably an at
least 40-fold selectivity, and most preferably an at
least 50 fold selectivity, for acetylcholinesterase as
opposed to butyrylcholinesterase, when measured by the
in vitro method by Thomsen et al., see below,
b) are capable of passing the blood brain barrier in
humans in vivo.
As will be understood from the above definition, a compound
can be subjected to well-defined and relatively short-
lasting tests (see below) to determine whether it fulfills
lS criterion a) above. Then, the likelihood whether the com-
pound will pass the blood brain barrier in humans in vivo
(criterion b)) can be assessed in a model. One such model
is a whole rat brain model in which rats are given the
acetylcholine esterase in vivo and are then killed where-
upon homogenate of the rat brain is examined with respectto the acetylcholinesterase activity; the result is then
; compared to the acetylcholinesterase activity in rat brains
not treated with acetylcholinesterase inhibitors. Another
rat model could be the measurement and comparison of acet-
ylcholinesterase activity in cerebrospinal fluid in vivo in
the same rat before and after treatment. If the compound
fulfills criterion a), and its likelihood of passing the
blood brain barrier has been established in one of the
above-described rat brain models, it will be a candidate
drug. An initial determination of toxicity is necessary in
cases before any effect in humans can be assessed; such
initial determination of toxicity can be performed by
pharmacologic tests in a manner known E~E se. After the
pharmacological tests, the capability of the candidate drug
of passing the blood brain barrier in humans in vivo can be
'
:
,

092/20327 PCT/DK92/00160
2~i~8~ ~ 16
determined by the method described below. If the candidate
drug has been found to possess this capability, it can be
passed to the testing proper. Optionally, the candidate
drug can be subjected to additional short-lasting tests,
such as the in vivo selectivity test described by Thomsen
et al., and a test to determine whether it increases cor-
tisol level in humans. Both of these tests give further
indication of whether the candidate drug has a spectrum of
properties equivalent to galanthamine with respect to what
must be presumed to be essential properties. Peripheral
side effects will be assessable when the effect is tested
clinically, which is acceptable from an experimental and
ethical point of view, provided the toxicity has first been
assessed by the above-mentioned pharmacological tests. With
respect to the final assessment of the candidate drug's
effect on fatigue syndrome, a rational and efficient design
of the assessment will involve an initial test on one or a
few patients and, provided the initial test is positive,
the above-mentioned conclusive double blind test. Because
of the well-defined and brief character of all of the
tests, and especially the well-defined n Yitro character
of the initial screening, the test series for identifying
useful functional equivalents of galanthamine is a reaso-
nable an not burdensome routine which is within the realm
of the person skilled in the art.
Functional equivalents and derivatives of galanthamine
which are useful in the method of the invention will be
employed in the same manner as stated herein for galan-
thamine. Whenever quantities of such a functional equiva-
lent or derivative are referred to herein, the quantitiesare given as the equipotent quantity of galanthamine hydro-
bromide with respect to inhibition of acetylcholinesterase,
that is, as the quantity of galanthamine hydrobromide which
results in the same inhibition of acetylcholine esterase in
the above-mentioned n vitro test according to Thomsen et
al as does the functional derivative or derivative.

- W O 92t20327 PC~r/DK92/00160
17 21~
The selectivity of the acetylcholinesterase inhibitor for
acetylcholinesterase as opposed to butyrylcholinesterase
can be determined by ln vitro and in vivo tests as de-
scribed by Thomsen and Kewitz in the above mentioned paper
Selective Inhibition of Human Acetylcholinesterase by
Galanthamine in vitro and in vivo, Life Sciences, Vol 46,
pp. 1553-1558 (1990), and T. Thomsen, H. Kewitz and 0.
Pleul, J. Clin. Chem. Clin. Biochem. 26 469-475 (1988). The
in vit-o test described by Thomsen and Kewitz in Life
Sciences, Vol 46, pp 1553-155~ (1990) is the one referred
to above in connection with criterion a) and whenever
numeric (10-fold, 20-fold, 40-fold) reference to selec-
tivity for acetylcholinesterase as opposed to butyryl-
cholinesterase is made in the claims. According to Thomsen
and Kewitz, galanthamine hydrobromide, when tested under
the conditions described, shows a 50-fold selectivity;
this selectivity value is taken as the "fixpoint" whenever
in vitro selectivities are discussed herein and could be
used, for the purpose of determining the selectivities for
other cholinesterase inhibitors, as a calibration value
which is the one to establish with galanthamine hydrobro-
mide in any repetition of thé experiment described by
Thomsen and Kewitz. Thus, with reference to this deter-
mination method, a preferred acetylcholinesterase inhibitor
is one which in the in vitro method described has an at
least 10-fold selectivity for acetylcholinesterase as
opposed to butyrylcholinesterase, such as an at least 20-
fold selectivity for acetylcholinesterase as opposed to
butyrylcholinesterase, e.g. an at least 40-fold selectivity
for acetylcholinesterase as opposed to butyrylcholineste-
rase.
A relatively easy commercially available selectivity test
which can be used as a practical tool in the screening of
candidate drugs is the test described in Example 1 herein.
The capability to pass the blood brain barrier ln vivo in
humans can be assessed by either by a test which could be

~ W092/20327 PCT/DK92/00160
2~088~ 18 ~-
called "Auditory brain stem response" or by a test which is
based on the measurement of CRH, ACTH and cortisol. The
rationale behind these tests, and the way they are per-
formed, is explained in the following:
:
The auditory brain stem response test is based on the
observation that manio-depressive patients are hypersensi-
tive to cholinergic influences, one manifestation hereof
being hypersensitivity to auditory signals as assessed by
; the increase of amplitude of auditory evoked potentials in
the nuclei of the auditory system in the brain stem, i.e.
on the "brain side" of the blood brain barrier. This hyper-
sensitivity manifests itself in a lower amplitude than in
normal humans when the person is not treated with a cholin-
ergic agent such as acetylcholinesterase inhibitor; and a
very significantly increase of the amplitude when the
person has received a cholinergic agent, provided, of
course, that the cholinergic agent is able to pass the
blood brain barrier and thus enter the nuclei of the audi-
tory system in the brain stem. See also example 3.
The other test based on the measurement of CRH (cortico-
tropic-hormone releasing hormone released from the hypotha-
lamus in the brain, and which releases both ACTH from the
adenohypophysis and cortisol from the adrenal medulla) and
ACTH (corticotropic hormone, which releases cortisol from
the adrenal medulla) is carried out by measuring the CRH,
ACTH and cortisol concentration in the blood in healthy
persons before and after medication with acetylcholineste-
rase. If the concentration of all three hormone are in-
creased after medication or at least CRH and cortisol are
increased it is proven that the acetylcholinesterase has
effect in the central nervous system, and since it is an ln
v vo experiment it is further proven that the acetylcholin-
esterase has passed the blood brain barrier.
As mentioned above, the selectivity of the acetylcholin-
esterase inhibitor can, as an additional characterization,
'
: ~.

W092/20327 ~ 3 ~ 3 PcT/DK92/ool6o
~ ~- 19
.. ..
optionally be expressed with reference to the in vivo
determinations performed by Thomsen and Kewitz on galan-
thamine and described in the above-mentioned paper Selec-
tive Inhibition of Human Acetylcholinesterase by Galan-
- 5 thamine in vitro and in vivo, Life Sciences, Vol 46, pp.
1553-1558 (lsso). With reference to this determination, a
preferred acetylcholinesterase inhibitor is one which, upon
administration in an amount of 10 mg to a healthy adult,
results in inhibition of at least 40% of the acetylcholin-
esterase activity in erythrocytes from the adult within
about 2-5 minutes and no substantial inhibition of butyryl-
cholinesterase therein, such as an acetylcholinesterase
inhibitor which, when administered in an amount of 10 mg to
a healthy adult, results in inhibition of at least 50% of
the acetylcholinesterase activity in erythrocytes from the
adult within about 2-5 minutes. For galanthamine, Thomsen
and Kewitz found 65~ inhibition of acetylcholinesterase in
the erythrocytes within 2 minutes after administration of
10 mg of galanthamine i.v. in a healthy volunteer, whereas
no inhibition of butyrylcholinesterase in plasma was seen.
Also these determinations are referred to in claims herein
and should, in connection with the evaluation of the cor-
responding selectivities of candidate drugs different from
galanthamine hydrobromide be considered the "calibration
fixpoints" which will be established with galanthamine
hydrobromide in any repetition of this experiment.
As mentioned above, it is possible that galanthamine,
galanthamine salts and galanthamine derivatives, due to the
special conformation of the galanthamine ring system, have
specific properties which are decisive for the remarkable
effect established according to the present invention.
Thus, according to one aspect of the invention, compounds
which are contemplated to be valuable and useful in the
treatment according to the invention are the compounds
having the formula II (formula II also represent galanth-
amine itself)
`
.
~; ' ' ' ,~ - ~
.

W092/20327 PCT/DK92/00160
,
; 20 (---
21088~
o~3 '
R2O ~ ~ R4 II
N
wherein Rl and R2 which may be the same or different each
represents a hydrogen atom or an acyl group, such as a
lower alkanoyl group, e.g. an acetyl group or a straight-
chained or branched alkyl group, e.g. methyl, ethyl,
propyl, or isopropyl; R3 is a straight or branched chain
alkyl, alkenyl or alkaryl group which is optionally sub-
stituted by a halogen atom or a cycloalkyl, hydroxy,alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl,
heteroaryl-alkyl, aroyl, aroylalkyl or cyano group; and R4
r~presents a hydrogen or halogen atom attached to at least
one of the ring carbons of the tetracyclic skeleton, with
lS the proviso that when R4 is in a position neighbouring the
nitrogen atom, then R4 is preferably different from halo-
gen, and salts thereof, such as a hydrobromide, hydrochlo-
ride, methylsulphate or methiodide.
In the compounds of formula I, alkyl moieties preferably
contain l to 8 carbon atoms, halogen atoms are preferably
fluorine, chlorine, or bromine, especially fluorine or
chlorine, aryl moieties are preferably phenyl, cycloalkyl
groups are preferably 3- to 7-membered rings, especially
cyclopropyl or cyclobutyl, and heteroaryl moieties are
preferably S- to 8-membered rings, e.g., thienyl, furyl,
pyridyl, pyrrolyl, or pyrizanyl.
Among the compounds of the formula I are those described in
EP-A-236684. The compounds of formula I may be prepared
~ ~ .

W092/20327 2 ~ PCT/DK92/00160
21
according to conventional techniques, including ~hose
described in EP-A-236684.
A broader range of compounds which, from the point of view
of structural similarity with galanthamine, are contempla-
ted to be valuable compounds useful in the method of theinvention are galanthamine derivatives of the general
formula I
A, ~ I
wherein the broken line represents an optionally present
double bond in one or the two of the positions shown, R
and R2 are each selected independently from the group
consisting of hydrogen, hydroxyl, amino or alkylamino,
cyano, sulfhydryl, alkoxy of 1-6 carbon atoms, alkylthio,
aryloxy, arylthio, R5-substituted aryloxy, R5-substituted
arylthio, aralkoxy, an aliphatic or aryl carbamyl group
wherein the aliphatic or aryl moiety may be R5 substituted
or unsubstituted, aralkylthio, R5-substituted aralkoxy, R5-
substituted aralkylthio, aryloxymethyl, R5-substituted
aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyl-
oxy, benzoyloxy, R5-substituted benzoyloxy, aryloxycarbonyl
and R5-substituted aryloxycarbonyl, R1 may also be alkyl of
up to 14 carbon atoms, or hydroxymethyl, R2 may also be
carboxymethyl, provided that at least one of R1 and R2 is
hydroxy, amino or alkylamino unless R7 or R8 is hydroxy-
methyl,
R3 is hydrogen, straight or branched chain alkyl of 1-6
carbon atoms, cycloalkylmethyl, phenyl, R5-substituted
phenyl, alkylphenyl, R5-substituted alkylphenyl, heterocyc-
.-
.

.W092/20327 . PCT/DK92/00160
;`21088~0 22 ~~~
lyl selected from ~- or ~-furyl, ~- or ~-thienyl, thenyl,
pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or
R'-substituted heterocyclyl, where R' is alkyl or alkoxy,
each R4 is independently selected from hydrogen, hydroxyl,
sulfhydryl, alkyl, aryl, aralkyl, alkoxy, mercaptoalkyl,
aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro,
amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro,
chloro, bromo, iodo, and trifluoromethyl,
R5 is selected from the same groups as R4,
R6 is hydrogen, halo, trifluoromethyl or alkyl of l to 4
carbon atoms, with the proviso that when R6 is in position
7 or 9, it is preferably not halo.
R7 is selected from the same groups as R4 or may be hy-
droxyalkyl of 1-2 carbon atoms,
R8 is hydrogen or hydroxymethyl,
Rg is hydrogen or alkyl of l to 6 carbon atoms, or when R2
is hydroxyl, Rg may be a moiety of formula I wherein Rg is
hydrogen and R2 is a linking bond; or
R2 and Rg may jointly form semicarbazone,
X is oxygen or NR5,
Y is nitrogen or phosphorus,
and methylenedioxy derivatives thereof with the proviso
that when X is O, R3 is not methyl when Rl is methoxy, R2
is hydroxy, and all R4 are hydrogen,
or a pharmaceutically acceptable acid addition salt
thereof.

W092/20327 ?~ PCT/DK92/00160
23
Examples of subclasses and specific compounds of the for-
mula II are given in WO 88/08708, which also discloses
methods for preparing the compounds II.
Galanthamine, galanthamine salts, galanthamine derivatives
and galanthamine functional equivalents, when suited there-
for, may be administered orally at a dosage of e.g. 5-lS0
mg per day, such as 10-60 mg per day, e.g. 10-50 mg, such
as 10-40 mg, per day, the dosage being adapted to the
patient and the patient's response. As mentioned above, the
treatment should often be started with a low dosage and
then increased until the suitable dosage has been
established. The dosage of galanthamine functional equiva-
lents or galanthamine derivatives is expressed as the
equipotent amount of galanthamine hydrobromide, the refe-
rence basis being the capability of inhibiting acetyl-
cholinesterase in the Thomsen et al. ln vitro test men-
tioned above.
Examples of parenteral administration ranges are 0.1-1000
mg per day, such as 5-1000 mg per day, e.g. 10-500 mg per
day, including 50-300 mg per day; lower dosages are often
preferred, such as 10-50 mg per day, e.g. 10-30 mg per day.
For the oral administration, galanthamine or a galanthamine
salt or derivative or a functional equivalent may be formu-
lated, for example, as an aqueous suspension or a solution
in aqueous ethanol or as a solid composition such as a
tablet or capsule. Suspensions or solutions for oral ad-
ministration are typically of a concentration of 1-50
mg/ml, more commonly 5-40 mg/ml, for example, 10-40 mg/ml,
typically 20-30 mg/ml of galanthamine. Divided doses into
the range 0.5-S mg/kg body weight per day are useful, in
some situations divided doses in the range of 0,1-3 mg/kg
body weight per day may also prove useful. Examples of
dosages are up to 2000 mg per day, such as 0.1-2000 mg per
day, or 5-2000 mg per day. Other ranges that should be

WO92/20327 PCT/DK92/00160
21~838~ 24
mentioned are 100-600 mg per day or 10-500 mg per day, such
as 10-50 or 10-30 mg per day. Typically, one might admini-
ster a dosage of 20-100 mg per day to a patient of a body
weight of 40-100 kg, although in appropriate cases such
dosages may prove useful for patients having a body weight
outside this range. However, in other instances dosages of
50-300 mg per day to a patient of a body weight of 40-100
kg may be also be very useful. In other cases, dosages as
low as ~0 mg and as high as 200 mg may be ~ppropriate for
persons in this body weight range.
Galanthamine and its acid addition salts form crystals.
They are generally only sparingly soluble in water at room
temperature; therefore, injectable compositions are normal-
ly in the form of an aqueous suspension. If necessary,
pharmaceutically-acceptable suspension aids may be emp-
loyed. Typically, such a suspension will be employed at a
concentration of 0.1-50 mg/ml, such as 1-50 mg/ml, more
commonly 5-40 mg/ml, for example, 5-30 mg/ml or 10-40
mg/ml, such as 10-30 mg/ml, especially 20-30 mg/ml of
galanthamine. As mentioned above, typical dosage rates when
administering galanthamine by injection are the range 0.01-
20 mg per day depending upon the patient. For example,
divided doses in the range 0,S-S mg/kg body weight per day
may prove useful. Typically, one might administer a dosage
of 5-50 mg per day to a patient of a body weight of 40-100
kg, although in appropriate cases such dosages may prove
useful for patients having a body weight outside this
range. In other cases, dosages as low as 5 mg and as high
as 200 mg per day may be appropriate for persons in this
body weight range.
Galanthamine and its pharmaceutically acceptable acid
addition salts, and its derivatives and functional equi-
valents, when suitèd therefor, may be administered by
subcutaneous, intravenous or intramuscular injection.
.

W092/20327 2 ~ PCT/DK92/00160
The parenteral dosage rate of galanthamine can also be
expressed by reference to the body weight of the patient;
in this case, a normal dosage rate will often be 0.l to 4
mg/kg body weight. Depot compositions will often deliver a
dosage rate of O.Ol to 5.0 mg/kg per day.
In preparing tablets or capsules, standard tablet or cap-
sule-making techniques may be employed. If desired, a
pharmaceutically acceptable carrier such as starch or
lactose may be used in preparing galanthamine or galan-
thamine equivalent tablets. Capsules may be prepared usingsoft gelatine as the encapsulating agent. If desired, such
capsules may be in the form of sustained release capsules
wherein the main capsule contains microcapsules of galan-
thamine or functional equivalents thereof which release the
contents over a period of several hours thereby maintaining
a constant level of galanthamine or its functional equi-
valent in the patient's blood.
The following specific formulations may find use according
to the invention:
Tablets or capsules containing 0.l, l, 2, 5, l0 and 25 mg
galanthamine hydrobromide or functional equivalent to be
taken four times a day, or a sustained-release preparation
delivering an equivalent daily dose.
Liquid formulation for oral administration available in 5
mg/ml and 25 mg/ml concentration.
Other interesting administration forms of galanthamine and
functional equivalents are suppositories, a slow-release
plaster, and other depot compositions.
All of the above-mentioned administration forms are pre-
pared in manners known ~er se.
, ~ ...... .. ..
: .

W092/20327 - PCT/DK92/00160
: 2~$~8~0 26
Although galanthamine must be considered as having a high
degree of safety, there have been certain side effects in a
few of the patients treated. These have been slight nausea
in about 30% of the cases (the nausea, however, disappear-
ing after about one week of treatment), vomiting and dizzi-
ness in 5-10% of the patients (also disappearing after
about one week of treatment in most cases), and more severe
side effects in 4-6% of the patients. These more severe
side effects must be considered acceptable in Vi2W of the
effect of the drug; however, in patients who are suspected
of developing arrhythmia, it should be considered to ad-
minister, e.g., atropine in combination with the treatment
according to the invention.
The administration forms for the cholinesterase inhibitors,
galanthamine, the galanthamine salts and the galanthamine
derivatives may be orally and parenterally. The administra-
tion being dependent on the patient's age and weight, and
on the daily life of the patient as well as the severity of
the disease.
Parenteral administration may comprise suitable injection,
e.g. intravenous, intramuscular, subcutaneous, as well as
transdermal or rectally administration or implantation of
e.g. suitable delivery devices, such as a intrathetical
device.
Formulations for parenteral use may be a solution or su-
spension, a plaster for transdermal application, or a
suppository.

W092t20327 PCT/DK92/00160
! 27
EXAMPLE 1
Test for cholinesterase activitv in blood samples
Method
SIGMA DIAGNOSTICS~ CHOLINESTERASE (PTC) kit, available from
Sigma Diagnostics, can be used for determining the activity
and selectivity of cholinesterase inhibitors. In the fol-
lowing, it is illustrated how the kit is used for the
determination of the activity and selectivity of Nivalin
(Galanthamine hydrobromide).
Reactions involved in the cholinesterase assay are as
follows:
esterase
Propionylthiocholine + H2O ~ Propionic Acid + Thio-
choline
Thiocholine + 5,5'-Dithiobis-2-Nitrobenzoic Acid
; 5-Thio-2-Nitrobenzoic Acid
5-Thio-2-Nitrobenzoic Acid is assessed by measuring the
absorbance at 405 nm. The rate of change in absorbance at
405 nm is directly proportional to cholinesterase activity.
The activity of erythrocyte cholinesterase may be calcu-
lated on the basis of the measurement of butyrylcholin-
esterase (pseudocholinesterase) in serum and cholinesterase
in hemolyzed whole blood (hemolysate), both measured simul-
taneously by the method described above, and evaluated
2S according to the hematocrit value according to the formula
HChE = (EChE x Hct*) + (PChE x (l-Hct*))
HChE- (PChE x (1-Hct*))
Therefore, EChE =
Hct*
.

WO92/20327 PCT/DK92~00160
,, .
21 a8 ~ ~ ~ 28
* Hematocrit value expressed as decimal e~uivalent (i.e.,
44% = 0.44.
- In the above formulae, EChE is erythrocyte cholinesterase
activity, PChE is plasma cholinesterase activity, HChE is
5 hemolysate cholinesterase activity, and Hct is hematocrit
value of the sample.
.
Another way of assessing the cholinesterase activity is to
measure the plasma cholinesterase and the cholinesterase in
s purified hemolyzed erythrocytes. By doing this, the values
10 are obtained directly.
Blood samples from 3 patients were tested with the Sigma
test. The tests were carried out with samples where no
Nivalin was added and with samples where 1.25 ~g/ml Nivalin
and 2.5 ~g/ml were added ln yitro. The results are shown
15 below in table 1.1.
;,
Table 1.1
Nivalin added Hemolysate Serum
20 ~g/ml ChE ChE
activity activity
_
0 1.00 1.00
1.25 0.96 0.98
25 2.50 0.86 0.97
_ _ . . _ . .
The results show a significant reduction of the hemolysate
cholinesterase activity with increased concentration of
galanthamine hydrobromide, whereas the data for the serum
activity do not show any statisticaIly significant change
. . .

~ W092/20327 PCT/DK92/00160
,~ 29 ~' &8~
as a response to the addition of the galanthamine hydrobro-
mide, which is an indication of a high selectivity of the
galanthamine hydrobromide with respect to acetylcholin-
esterase as opposed to butyrylcholinesterase.
Selectivity for acetylcholinesterase in erythrocytes op-
posed to butyrylcholinesterase is contemplated to reflect
the selectivity for acetylcholinesterase at nicotinic
receptor sites opposed to the acetylcholinesterase at
muscarinic receptor sites.
., .
This test may be used as a screening for candidate choline-
sterase inhibitors with respect to their selectivity.
EXAMPLE 2
J
Formulations of tablets containing galanthamine
'~ Com~osition of 1 tablet containina 1 mq aalanthamine
15 Galanthamine hydrobromide 0.001 g
Calcium phosphate 0.032 g
Lactose 0.005 g
Wheat Starch 0.0056 g
Microcrystalline Cellulose 0.015 g
20 Talc 0.0007 g
Magnesium Stearate 0.0007 g
Composition of 1 tablet containing 5 mg aalanthamine
Galanthamine hydrobromide 0.005 g
Calcium phosphate 0.024 g
25 Lactose 0-004 g
Wheat Starch 0-004 g
Microcrystalline Cellulose 0.04 g
Talc 0.002 g
Magnesium Stearate 0.001 g
.

~ W092/20327 PCT/DK92/00160
2 ~
- !
composition of 1 tablet containing 10 mq galanthamine
Galanthamine hydrobromide 0.010 g
Lactose 0.040 g
Wheat Starch 0.0234 g
5 Microcrystalline Cellulose 0.0374 g
Talc 0.0036 g
Magnesium Stearate 0.0012 g
Gelatin 0.0044 g
Preparation
j:
All the tablets are prepared according to routine tablet-
ting procedures.
. .
~ EXAMPLE 3
. .
Diagnostic criteria for patients with the Chronic Fatiaue
Syndrome ~CFS)
' .
To diagnose Chronic Fatigue Syndrome a guideline for re-
search has been published (5).
- A syndrome characterized by fatigue as the principal
syndrome.
- A syndrome of definite onset that is not life long.
- The fatigue is severe, disabling and affects physical
and mental functioning.
- The symptom of fatigue should have been present for a
minimum of 6 months during which it was present for
more than 50~ of the time.
- Other symptoms may be present, particularly myalgia,
mood and sleep disturbances.

W092/20327 ~ 1 ~ 8 3 ~1~ PCT/DK92/00160
, 31
- Certain patients should be excluded from the defini-
tion. They include:
Patients with established medical conditions
known to produce chronic fatigue (eg. severe
anemia). Such patients should be excluded ir-
respective of whether the medical condition is
diagnosed at presentation or only subsequently.
All patients should have a history and phvsical
examination performed by a competent physician.
Patients with current diagnoses of schizophre-
nia, manic depressive illness, substance abuse,
eating disorder, or proven organic brain disease.
Other psychiatric disorders (including depressive
illness, anxiety disorders, and hyperventilation
syndrome) are not necessarily reasons for ex-
clusion.
EXAMPLE 4
Diaanostic criteria for patients with the Post-infectious
Fatiaue Svndrome ~PIFS)
The patients must fulfill the criteria for CFS as defined
above and should also fulfill the following criteria:
- A definite evidence of infection at onset or presenta-
tion
- The syndrome is present for at least 6 months after
onset of the infection.
- The infection has been corroborated by laboratory
evidence.
.
.
' . ~ ' ''
..
:

W092/20327 PCT/DK92/00160
8~3 32
EXAMPLE 5
Double-blind cross-over trial of the effect of qalanthamine
on Chronic Fatique Syndrome (CFS)
20 persons suffering from Chronic Fatigue Syndrome ful-
filling the criteria described in example 4 or 5.
Method
Each patient received treatment for a minimum of 8 weeks.
The first 2 weeks incorporated an escalating schedule to
stabilise the patient on an appropriate dose.
The trial was running for eight weeks.
11 of the persons were randomly allocated to galanthamine
treatment, and the remaining 9 to placebo treatment. The
protocol for the trial made provisions for the clinician to
opt after two weeks of treatment for transfer to the alter-
native treatment. The switch to the alternative treatment
was made if he regarded the patient as having failed to
benefit from the 2 weeks therapy.
The data available for the evaluation covered groups of
patient-completed visual analogue scales to assess sleep
disturbance, fatigue, myalgia, work capacity/satisfaction,
and dizziness, together with time per response on a visual
search task.
Results
The results of the analysis of data from the visual ana-
logue scales during the first two weeks of treatment are
shown in table 6.1.

W092/20327 2 ~ PCT/DK92/00160
33
In order to assess any underlying, overall performance
difference between the galanthamine and placebo treated
patients, the median (the statistic which differentiates
the upper and lower 50% of scores) of the changes across
all scales, was computed for the placebo treated patients.
Using this median as an index of average "placebo respon-
se", it was found that 68.18% of galanthamine treated
patients changes on the analogue scales fall above the
placebo median, a difference tfrom the top 50% of placebo
treated patients) which is statistically significant (exact
p = 0.033). This demonstrates an underlying trend for CFS
patients treated with galanthamine to generate more benefi-
cial changes on these visual analogue scales, which cannot
be explained as a 'placebo resF~nse'.
Turning from the patients' own evaluation of therapeutic
benefit, to the clinicians' assessment of response during
the first two weeks of treatment, it was found that at this
point all 9 of the patients randomly allocated to the
placebo were transferred to galanthamine, whilst only l of
the ll patients receiving galanthamine was transferred to
placebo treatment. Such a difference (ie. 9/9 vs l/ll) is
highly significant (exact p = 0.00006). It is worth noting
that the one patient transferred from galanthamine to
placebo, after 2 weeks on placebo was found to have failed
to respond and was returned to galanthamine.
. . .
,

WO 92/20327 . PCT/DK92/00160
~ 80 34
TABLE 6.1
.
,
MEANS(ST,~NDARD ERRf~RS)()F VISU~L~NAL()(iUE S~ALES
r ,~
J Scalc Trc;~ cnl (N) B.lsclinc Arlcr I Wcck Aflcr 2 Wcck~ ¦
j Slccp(i~ nlll;llllinc (I l) 2(1.71Y (2.1.1) 17.')() (2.25) IX.. 12 (2.(J~) I
I Di~turhancc .. ~ . .... _ . --~1
rl~c~l~o (()) 22.(J(~ ) 1').51 (2.~) 1~.22 (2.~J~I)
(i~l;lnlh;l~ c (I I) ¦ 2').41 (1.(~1) 2~).7fi t I 7~) 25.21 (2.. 12
I F;lliy~uc l . _ .
;Iccl-~ ~')) 1 2X.52 (l.~)7) 27.(~7 (2.2fi) 2().53 (1.77)
i;ll;llllll;llllinc (11! 17.~X (~).7~) 151~.s (().73) 1.~ 5~Y (1.2
I Mv~lci~
Pl;lcct)o (~)) 17.26 ((I.71) lfi.().l (1.()2) 1~ )t)
Wnrk(i;ll;lnlll;lminc ( I I ) ¦ ~ ( I .17) I I fi I ( I .2X) () fi4 (1.(11
(~ap~cilv/ l
S~lisr;lc~ion Pl;lccl~o (~ ~ /) o 1., 1 4~ ( I .21) !
(;DI;Illlh;llllinc (I l) ~.. ~1 ((1.~)~) .S.R~J (().~()) .S.(,' ((1.~)(l) 1
Mcmorv 11
Pl;lccllo (~)) 6.(,~ (11.75) 5.fJfi (11.~l) ~.()2 (() `~1) Jl
l (;~i~nlll;lnlinc (11) I) (1.5 (1.2()) 9.fi() ( I .79) X.7') ( I .X l ) ..
I Dizzinc~s _
rl;lccl-o (')) (~.47 (I.fil) f~ ().7X) 7.~ (2.(~1)
The changes on the visual analogue scales of all galan-
thamine treated patients during treatment has been as-
sessed, both those patients randomly allocated to galan-
thamine and those transferred from placebo, during the
total eight weeks of the trial. These data are presented in
Table 6.2.
.~ . ~ . . .. . .

W O 92/20327 ~ PC~r/DK92/00160
: 35
TABLE 6.2
MEANS (~STANDARV ERR(?RS) ()F (;ALANTIIAI~IINE TREATED PATIENTS ()1`1
V18UAL ANALO(iUE S~ ALES
Sc~lc 13~sclin~ I Wccl; 2 Wcclis ¦ ~I Wccks 13 Wccks
N = I~J N = I') N = I') ¦N--18 N = 17
Slee p1 ~).45 (1.8:~) 17.26 (1.68) ~15.51 (1.~) 1) I I .P~9 (1.95) I (1.8f5 ( I .93)
Faliguc281)U (1.2~)2(,.()3 (1.77) 2U.64 (2.l)~J) 17.12 (2.15) ; 7.81 (2.Z I ) ¦¦
Mval~ia1().32 (1~ )1'$.25 (1).8~)) 11.21 (1.12) 12.(11 (1.15) IU.51 (().~)8) ¦¦
Work9.2t (IJ.83)IU.22 (1.117) 8.21 (1.17) 7.411 (1.25)7.34 (1.12) ¦¦
Mcmorv5.10 (I~.fi~)5.~ 1.61) 1 79 (n.5~)) 4.33 (0.70)4.5() (U.fi8)
Dizzincss 8.3~ (I.lt;) 8.9.) 11.~1) 6.')4 (1.411) 6.3U (1.32) 4 77 (1.23)
Statistically significant changes during treatment are
observed on the scales assessing sleep disturbance (p
<0.001), fatigue (0.001), myalgia (p <0.001), work capaci-
ty/satisfaction (p <0.001), and dizziness (p <o.001).
Comparable data to those above on the average time per
response on a visual search task are as follows in Table
6.3:
TABLE 6.3
B;lsclinc I Wcck2 Wccks I Wccks 8 Wccks
N = 19 N = 19 N = 18 N = 18N ~ 17
;
16-79(0-36) 1~-24(~).40) 5.51 (U.43) ~ 3(0.40) 1 5.2S(0.31)
Statistical analysis demonstrates that changes during
treatment on this variable are significant (F = 4.356;
4/60, p <0.001).
Data from the Cognitive Failures Questionnaire are avail-
able for a~l galanthamine treated patients at baseline and

W092t20327 PCT/DK92/00160
21 0~ 36
after 6 and 8 weeks of treatment. These are presented in
Table 6.4:
TABLE 6.4
B;l~clin~ I Wcck~ ,~ Wcck.
N = I~) N = 17 N = 17
_
~7 7 1 (1 5f)) ~7) ~7 (}.71)
~ ~ .
Statistical analysis demonstrates that changes during
treatment on this variable are significant (F = 5.339;
2/30, p <0.00l).
CONC~USIONS
The present data appear to provide clear and consistent
evidence in favour of the therapeutic efficacy of galan-
thamine in the treatment of CFS. This evidence is derived
from an interpretation of the patients' overall self-evalu-
ation of the beneficial effects of treatment, and form the
fact that an experienced, "blind" clinician transferred all
placebo patients to active treatment after only two weeks
of treatment, and made a comparable switch to placebo
treatment in only one patient receiving galanthamine.
Additional evidence of the beneficial effects of galan-
thamine comes form the observed significant improvements ona visual search task (a well validated test of concen-
tration and attention), and similar improvements on a
questionnaire designed to evaluate cognitive failures.

W092/20327 2 ~ g ~ PCT/DK92/00160
37
EXAMPLE 6
Auditory brain stem res~onse
Methods
Electrical potentials caused by click-stimulation in the
ears are measured with electrodes positioned outside on
the head of the examined parson. In the configuration of
the potentials are components from the brain stem and the
brain.
Persons
A patient suffering from bipolar manio-depression in the
depressive state and a healthy person, respectively.
Drua
Tablet containing 10 mg galanthamine
Results
Figures lA, lB, 2A and 2B show the potentials from a de-
pressive patient and a healthy person, both treated and
untreated.
Figures lA, and 2A show that in the depressed patient, the
auditory brain stem response without treatment has a much
smaller, almost half, amplitude of the potential compared
to the amplitude of the untreated healthy person.
Furthermore, figures lA and lB show a dramatically increase
of the amplitude in the treated depressive patient compared
to untreated persons.
''~

W092/20327 PCT/DK92/00160
2~ 38 1~-
Also, from figures 2A and 2s it is seen that the potentials
do not change from the untreated person to the treated
person.
- Conclusion.
From the results in the depressed person it is seen that
the potentials change after treatment with galanthamine,
such as explained above. This means that galanthamine r.ust
be able to cross the blood-brain barrier, since it is
possible to inhibit in synapsis in the brain stem, which is
positioned on the "brain side" of the blood-brain barrier.
LEGENDs TO FIGURES
Fig. l A shows the auditory evoked response of a depressed
patient (a manio depressed patient in the depressed state)
without treatment with galanthamine.
Fig. l B shows the auditory evoked response of a depressed
patient (the same as in fig. l A) 2 hours after treatment
with lO mg of galanthamine.
Fig. 2 A shows the auditory evoked response of a healthy
person without treatment with galanthamine.
Fig. 2 B shows the auditory evoked response of a healthy
person (the same as in fig. 2 A) 2 hours after treatment
with lO mg of galanthamine.